La cadena de opciones muestra datos clave de las opciones de acciones de ALPHAPOLIS CO LTD by ALPHAPOLIS CO LTD a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ALPHAPOLIS CO LTD by ALPHAPOLIS CO LTD..

ALPHAPOLIS CO LTD by ALPHAPOLIS CO LTD (OTC:APPLF) Bolsa, Cadena de Opciones

ALPHAPOLIS CO LTD by ALPHAPOLIS CO LTD

Three Midwest cities are emerging as affordable housing havens, requiring much less than the typical six-figure salary <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">needed for homeownership in many U.S. markets</a>. Rockford, Illinois; Akron, Ohio; and Canton, Ohio, have secured spots among Realtor.com's top 20 hottest housing markets, offering median home prices around $250,000 – well below the national median of $424,950.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes and you only need $100</a>.</li>
<li>This company is giving accredited investors an opportunity to invest in this $2 billion fund, <a href="https://www.benzinga.com/money/ignite-funding">with three decades in business they boast an impressive track record of double-digit returns.</a></li>
</ul>
&#8220;The typical [monthly] mortgage payment, assuming a 10% down payment, would be $1,455 or less in these areas,&#8221; reports Hannah Jones, senior economic research analyst at Realtor.com. &#8220;Including tax and insurance costs, the minimum recommended income to afford this payment is roughly $73,000, about 10% less than the national median household income.&#8221;
Rockford, Illinois, leads the group with a median list price of $242,000, attracting buyers with its proximity to Chicago and Milwaukee. Local real estate agent David Dale Johnson of Berkshire Hathaway HomeServices told Realtor.com that his market has had strong activity. &#8220;Inventory levels are still low in Rockford," he said. "Some areas of the Rockford market still see full price or greater offers.&#8221;
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% – 9% are protected by resilient assets, buffering against losses.</a>
Akron, Ohio – the birthplace of NBA superstar LeBron James – presents an attractive option at $228,000. Homes sell in just 36 days, 22 days faster than the national average. The city&#8217;s appeal extends beyond affordability, according to Gregg Mervis, president of the Akron/Summit Convention &amp; Visitors Bureau. &#8220;Greater Akron is an exceptional location that blends urban excitement with natural beauty.&#8221;
Canton, Ohio, with a median price of $252,000, recently topped the Wall Street Journal/Realtor.com Housing Market Ranking. Local expert Paul Gabrail told Realtor.com there is an investment opportunity in the area. &#8220;In terms of ROI, if you can buy a property for a relatively low price while the nation&#8217;s income goes up, you&#8217;ll probably do better in cities like Canton versus bigger cities in the West,&#8221; he said.
See Also: ‘Beating the market through ethical real estate investing' –<a href="https://www.benzinga.com/money/invest-with-roots"> this platform aims to give tenants equity in the homes they live in while scoring 17.38% average annual returns for investors – here&#8217;s how to join with just $100</a>
These Midwestern markets offer unique advantages beyond price points. Rockford provides free college tuition at Northern Illinois University for qualified residents, while Akron has strong climate resilience with just 1.8% of properties at risk of natural disasters over the next 30 years. Realtor.com noted that Canton's status as the birthplace of the NFL and home to the Pro Football Hall of Fame adds cultural significance to its economic appeal.
The continued strength of these markets, consistently ranking since February 2022, suggests a sustainable trend rather than a temporary shift. Their affordability, quality of life and economic opportunity make them viable alternatives <a href="https://www.benzinga.com/real-estate/24/11/41876775/u-s-homebuyers-are-now-56-on-average-as-younger-generations-struggle-with-wildly-unaffordable-market-housing-expert-warns">for homebuyers priced out of larger metropolitan areas</a>.
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate –<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

You Don't Need A $100K Salary To Afford A Mortgage In These 3 Livable Cities – Unsurprisingly, In The Midwest

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) with a Buy and maintains $5.5 price target.

News

Price Target

Reiteration

Analyst Ratings

LPTX

HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $5.5 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and maintains $10 price target.

AFMD

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

UBS analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with a Buy rating and announces Price Target of $21.

Initiation

UBS Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $21

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) with a Buy and lowers the price target from $32 to $30.

GNLX

HC Wainwright & Co. Maintains Buy on Genelux, Lowers Price Target to $30

BMO Capital analyst John Kim upgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Underperform to Market Perform and raises the price target from $19 to $21.

Upgrades

BMO Capital Upgrades Independence Realty Trust to Market Perform, Raises Price Target to $21

EYEN

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

POOL

Pool Corp shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Domino's Pizza shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Baird analyst Shrenik Kothari maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and raises the price target from $385 to $425.

PANW

Baird Maintains Outperform on Palo Alto Networks, Raises Price Target to $425

ULTA

Ulta Beauty shares are trading lower after Berkshire Hathaway cut its position in the stock.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and maintains $3 price target.

RNAZ

HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/66585980a3067c00012c48c0/david-roman">Goldman Sachs analyst David Roman </a>initiated coverage on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral rating and announced a price target of $108. HealthEquity shares closed at $95.70 on Thursday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $26.02 on Thursday. <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41494343/analyst-expectations-for-mastecs-future">Stifel analyst Brian Brophy</a> initiated coverage on EMCOR Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy rating and announced a price target of $600. EMCOR shares closed at $498.11 on Thursday. <a href="https://www.benzinga.com/quote/EME/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Harry Read initiated coverage on Insight Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Buy rating and announced a price target of $220. Insight Enterprises shares closed at $152.63 on Thursday. See how other analysts view this stock.</li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with an Outperform rating and announced a price target of $190. Johnson &amp; Johnson shares closed at $151.87 on Thursday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png" alt="" class="wp-image-650063" style="width:716px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

NSIT

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $5.36 million which beat the analyst consensus estimate of $2.69 million by 99.29 percent. This is a 2.42K percent increase over sales of $213.00 thousand the same period last year.

SLGL

Sol-Gel Technologies Q3 EPS $(0.01) Beats $(0.13) Estimate, Sales $5.36M Beat $2.69M Estimate

Baird analyst Wesley Golladay maintains Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) with a Neutral and raises the price target from $26 to $29.

Baird Maintains Neutral on Kite Realty Gr Trust, Raises Price Target to $29

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Baird analyst Jack Allen maintains MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Outperform and lowers the price target from $8 to $4.

INKT

Baird Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $4

Citigroup analyst Beatrice Lam downgrades Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) from Buy to Neutral and lowers the price target from $2.3 to $0.5.

Downgrades

Citigroup Downgrades Gogoro to Neutral, Lowers Price Target to $0.5

HC Wainwright &amp; Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and maintains $8 price target.

PSTV

HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target

Baird analyst Joel Beatty maintains Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) with a Outperform and raises the price target from $6 to $7.

Comments

ALPHAPOLIS CO LTD by ALPHAPOLIS CO LTD

ALPHAPOLIS CO LTD by ALPHAPOLIS CO LTD (APPLF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL